Calprotectin for Rapid Diagnostic Infection Spontaneous of Ascites (Ca-DRISLA)

The Ratio of Ascites Calprotectin to Total Protein is a Diagnostic and Prognostic Marker for Spontaneous Bacterial Peritonitis in Liver Cirrhosis

The prognosis of spontaneous bacterial peritonitis (ISLA) remains a serious complication of cirrhosis. Rapid diagnosis of ISLA is a key issue for improving the prognosis. The determination of calprotectin in ascites, used for the diagnosis of infection of ascitic liquid, could allow the diagnosis in a very short time (about 30 minutes). To date, the determination of calprotectin in ascites was not evaluated properly. The investigators would thus evaluate the interest of the determination of calprotectin in ascites for the rapid diagnosis of ISLA in cirrhotic patients, like you, hospitalized for decompensation of their disease. The main purpose of this pilot study will determine the optimal threshold calprotectin in ascites for diagnosis of ISLA.

Study Overview

• Status: Unknown
• Conditions: Rapid Diagnosis of Spontaneous Infection of Ascitic Fluid
• Intervention / Treatment: Other: dosage of calprotectin

Detailed Description

The occurrence of ascites in cirrhotic patients is a frequent event (about half of these patients developed ascites after 10 years of evolution) and marks an evolutionary turning point in the natural history of cirrhosis (30% survival at 5).

The spontaneous bacterial peritonitis (ISLA) is the leading infectious complication cirrhotic patient (prevalence of 10-30%). Half of these ISLA are already present on admission of the patient and over 20% of these infections are totally asymptomatic. The delay processing of ISLA causes heavy mortality. Even when antibiotic treatment is started immediately after the diagnosis of ISLA, in-hospital mortality remains high (about 20%) and mainly related to the development of severe sepsis, septic shock and hepatorenal syndrome; the medium-term prognosis remains severe as also survival after an episode of ISLA is 30-50% at 1 year. Therefore, the surviving patients with a first episode of ISLA are candidates for liver transplantation. Given the major prognostic implications and the asymptomatic nature of these infections, examination of ascites with neutrophil count (ANC) and bacteriological cultures still recommended during any puncture, which increases support. This is why clinicians are sensitive to processes that simplify the diagnosis of ISLA or make it faster.

The measurement of calprotectin in ascites could be of major interest for the rapid diagnosis of ISLA. It is a glycoprotein of 36 KDa fixing calcium and zinc, synthesized by neutrophils (where it represents 60% of the soluble proteins from the cytosol) as well as monocytes and macrophages in the lower concentration. It has anti-bacterial and anti-fungal, immunomodulatory and pro-apoptotic. Its synthesis is increased in case of inflammation and its rate reflects, in inflammatory bowel disease, the severity of the inflammation of the bowel wall. Fecal calprotectin allows to discriminate inflammatory bowel disease (IBD) functional impairment of the gastrointestinal tract (irritable bowel syndrome) in symptomatic patients and also seems more powerful than other non-specific markers of inflammation (CRP, sedimentation rate, leukocytosis) to make this distinction; again, this biological marker allows therapeutic monitoring for patients with IBD.

The reference technique proposed by the laboratory for assaying BÜHLMANN calprotectin is a quantitative ELISA in a stool sample or ascites but the Quantum Blue® Reader offers a faster quantitative measure (in 12 minutes). It consists of a sandwich immunoassay including the speed could be advantageously used for the diagnosis of ISLA. However, few studies have evaluated the assay of plasma calprotectin or in ascites in cirrhotic patients. A high plasma concentration of calprotectin could have a prognostic value in alcoholic cirrhosis, as a high concentration of calprotectin in ascites in decompensated cirrhosis.

• Study Type: Observational
• Enrollment (Anticipated): 218

Contacts and Locations

• Study Contact: Name: Delphine WEIL-VERHOVEN, MD; Email: dweil@chu-besancon.fr

Study Locations

• France
  • Besançon, France, 25000
    • Recruiting
    • CHRU Besançon
    • Contact: Delphine WEIL-VERHOVEN, MD; Email: dweil@chu-besancon.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

cirrhotic patients over 18 years, with ascites and hospitalized for complications of their cirrhosis: ascites decompensation first or recurrent ascites requiring prolonged hospitalization (> 2 days), gastrointestinal bleeding, encephalopathy, etc.

Description

Inclusion Criteria:

• Man or woman over 18 years
• Presence of ascites due to cirrhosis
• Hospitalization for a complication of cirrhosis (first or recurrent ascites ascites decompensation requiring prolonged hospitalization, gastrointestinal bleeding, encephalopathy, etc ...).

Exclusion Criteria:

• Patients with ascites admitted to the hospital for a suspected infection and receiving an antibiotic for more than 12 hours (patients with antibiotic prophylaxis with norfloxacin with a clinical suspicion of ISLA will be included in the study (there may be in this case ISLA germs resistant to quinolones).
• Outpatient hospital to perform paracentesis evacuative
• Chylous ascites,
• Hemorrhagic Ascites
• Ascites not related to portal hypertension (peritoneal carcinomatosis, pancreatic ascites, tuberculosis, etc ...)
• comatose patients under guardianship or does not have all their mental faculties

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measurement of the calprotectin level in ascitic fluid with Quantum Blue® Reader	Establish an optimal threshold calprotectin in ascites for diagnosis of ISLA and evaluate the performance of calprotectin in ascites in cirrhotic patients with ascites due to portal hypertension only.	18 months

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Besancon
• Collaborators: BÜHLMANN Laboratories

Study record dates

Study Major Dates

• Study Start: February 1, 2015
• Primary Completion (Anticipated): February 1, 2019
• Study Completion (Anticipated): August 1, 2019

Study Registration Dates

• First Submitted: July 28, 2016
• First Submitted That Met QC Criteria: August 2, 2016
• First Posted (Estimate): August 5, 2016

Study Record Updates

• Last Update Posted (Actual): July 18, 2018
• Last Update Submitted That Met QC Criteria: July 17, 2018
• Last Verified: July 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Ascites
• Other Study ID Numbers: P/2015/243